First Tracks Biotherapeutics, Inc.
TRAXNasdaqCIK 2091349HealthcareFiscal year ends Dec 31
Income statement
| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 |
|---|---|---|---|---|---|
| Research and development | $m | 41.5Research and development, period not labelled, three months to 2025-03-31$41.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 39.3Research and development, period not labelled, three months to 2025-06-30$39.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 34.0Research and development, Q1 FY2026, three months to 2026-03-31$34.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 25.6Research and development, Q2 FY2026, three months to 2026-06-30$25.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Operating income | $m | (51.3)Operating income, period not labelled, three months to 2025-03-31−$51.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | (45.9)Operating income, period not labelled, three months to 2025-06-30−$45.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | (52.8)Operating income, Q1 FY2026, three months to 2026-03-31−$52.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | (34.9)Operating income, Q2 FY2026, three months to 2026-06-30−$34.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Net income | $m | (47.2)Net income, period not labelled, three months to 2025-03-31−$47.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | (42.4)Net income, period not labelled, three months to 2025-06-30−$42.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | (50.5)Net income, Q1 FY2026, three months to 2026-03-31−$50.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | (33.4)Net income, Q2 FY2026, three months to 2026-06-30−$33.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Diluted EPS | $ per share | not reported | (1.47)Diluted EPS, period not labelled, three months to 2025-06-30−$1.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | not reported | (0.95)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Basic EPS | $ per share | not reported | (1.47)Basic EPS, period not labelled, three months to 2025-06-30−$1.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | not reported | (0.95)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.95 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
Balance sheet
| Line item | Unit | period not labelled2024-12-31 | period not labelled2025-03-31 | period not labelled2025-06-30 | period not labelled2025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $m | not reported | not reported | not reported | 238Cash and equivalents, period not labelled, at 2025-12-31$238.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 248Cash and equivalents, Q1 FY2026, at 2026-03-31$248.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 168Cash and equivalents, Q2 FY2026, at 2026-06-30$168.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Current assets | $m | not reported | not reported | not reported | 316Current assets, period not labelled, at 2025-12-31$316.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 289Current assets, Q1 FY2026, at 2026-03-31$289.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 178Current assets, Q2 FY2026, at 2026-06-30$177.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Total assets | $m | not reported | not reported | not reported | 331Total assets, period not labelled, at 2025-12-31$330.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 291Total assets, Q1 FY2026, at 2026-03-31$290.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 183Total assets, Q2 FY2026, at 2026-06-30$183.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Current liabilities | $m | not reported | not reported | not reported | 31.0Current liabilities, period not labelled, at 2025-12-31$31.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 33.1Current liabilities, Q1 FY2026, at 2026-03-31$33.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 12.4Current liabilities, Q2 FY2026, at 2026-06-30$12.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
| Shareholders' equity | $m | 392Shareholders' equity, period not labelled, at 2024-12-31$391.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 358Shareholders' equity, period not labelled, at 2025-03-31$357.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 271Shareholders' equity, period not labelled, at 2025-06-30$270.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 287Shareholders' equity, period not labelled, at 2025-12-31$287.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 257Shareholders' equity, Q1 FY2026, at 2026-03-31$257.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure | 169Shareholders' equity, Q2 FY2026, at 2026-06-30$168.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346931.Report this figure |
Cash flow
| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 |
|---|---|---|---|---|---|
| Operating cash flow | $m | (45.0)Operating cash flow, period not labelled, three months to 2025-03-31−$45.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | (38.6)Operating cash flow, period not labelled, three months to 2025-06-30−$38.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-346931. Derived: 6-month figure less the 3-month figure.Report this figure | (32.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$32.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | (31.9)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$31.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-346931. Derived: 6-month figure less the 3-month figure.Report this figure |
| Capital expenditure | $m | 0.0Capital expenditure, period not labelled, three months to 2025-03-31$35.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 0.0Capital expenditure, period not labelled, three months to 2025-06-30$39.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-346931. Derived: 6-month figure less the 3-month figure.Report this figure | 0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224190.Report this figure | 0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-346931. Derived: 6-month figure less the 3-month figure.Report this figure |
Shares
| Line item | Unit | period not labelled2025-06-30 | Q2 FY20262026-06-30 |
|---|---|---|---|
| Diluted shares (weighted) | m shares | 28.8 | 35.0 |
Shares outstanding: 35.73m at Aug 7, 2026, from the cover of the 10-Q filed Aug 12, 2026.
Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.